Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Kymriah deal to stay despite CMS shift on proposed pilot

July 13, 2018 6:55 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said on July 9 an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a demonstration program including indication-based pricing.

A CMS spokesperson told BioCentury the agency "reviewed Novartis’s proposed demonstration and then decided to go in a different direction," but declined to provide details...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Novartis AG